Journal of Clinical Endocrinology & Metabolism, Vol 72, 1278-1285, Copyright © 1991 by Endocrine Society

ARTICLES

Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease

GM Christman, JF Randolph, RP Kelch and JC Marshall
Department of Internal Medicine, University of Michigan, Ann Arbor 48109.

Polycystic ovarian disease (PCO) is characterized by hyperandrogenism, ovulatory dysfunction, and altered gonadotropin secretion. Mean plasma FSH concentrations are low, while LH is elevated in a majority of patients. LH pulsatile secretion has been shown to occur at rapid follicular phase frequencies (approximately one pulse per h) in PCO, suggesting persistent rapid frequency GnRH secretion in this disorder. Anovulatory women with PCO were given estradiol (E2; Estraderm skin patches) and progesterone (P; vaginal suppositories) to produce midluteal concentrations for 21 days. The aim was to determine if E2 and P would slow LH (GnRH) pulse frequency and if this would result in augmented FSH secretion and follicular development after withdrawal of E2 and P. Plasma LH was measured every 10 min for 8 h before, during (days 10 and 20), and 7 days after withdrawal of E2 and P (day 28). On each of these study days FSH was measured hourly, and E2 and P were measured every 2 h. After sampling, GnRH (25 and 250 ng/kg, iv) was given to assess pituitary responsiveness. Follicular development was monitored by vaginal ultrasound through day 34 of the study. Basal LH frequency was 8.5 +/- 0.5 pulses/8 h (mean +/- SEM). During E2 and P, LH pulse frequency fell to 3.3 +/- 1.0 (10 days) and 2.3 +/- 0.8 (20 days), 39% and 27% of the basal value, respectively, and subsequently increased to 5.6 +/- 0.7 (66% of basal) 7 days after withdrawal of E2 and P. LH pulse amplitude (basal, 7.2 +/- 1.5 IU/L) was not reduced until day 20, but remained suppressed (3.9 +/- 1.1 IU/L) on day 28. As a result, mean LH (basal, 21.0 +/- 3.5 IU/L) fell progressively during E2 and P, to 3.8 +/- 1.2 IU/L on day 20, and remained low (39% of basal) 7 days after steroid withdrawal. Mean plasma FSH (basal, 7.1 +/- 0.9 IU/L) also fell during steroid administration, but in contrast to LH, had risen to 93% of the basal value by 7 days after E2 and P. LH release in response to exogenous GnRH revealed marked initial responses which did not decrease until day 20, but remained suppressed (8% of basal) after withdrawal of E2 and P. FSH responses were also suppressed on day 20, but had increased to 75% of the basal value by day 28. Initiation of follicular development occurred in all patients, and the lead follicle measured 12.3 +/- 0.8 mm 13 days post-E2 and P. Ovulation occurred in one patient.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D. H Abbott, D. K Barnett, J. E Levine, V. Padmanabhan, D. A Dumesic, S. Jacoris, and A. F Tarantal Endocrine Antecedents of Polycystic Ovary Syndrome in Fetal and Infant Prenatally Androgenized Female Rhesus Monkeys Biol Reprod, July 1, 2008; 79(1): 154 - 163. [Abstract] [Full Text] [PDF]

				S. S. Srouji, Y. L. Pagan, F. D'Amato, A. Dabela, Y. Jimenez, J. G. Supko, and J. E. Hall Pharmacokinetic Factors Contribute to the Inverse Relationship between Luteinizing Hormone and Body Mass Index in Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1347 - 1352. [Abstract] [Full Text] [PDF]

				Y. L. Pagan, S. S. Srouji, Y. Jimenez, A. Emerson, S. Gill, and J. E. Hall Inverse Relationship between Luteinizing Hormone and Body Mass Index in Polycystic Ovarian Syndrome: Investigation of Hypothalamic and Pituitary Contributions J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1309 - 1316. [Abstract] [Full Text] [PDF]

				M. Manikkam, T. L. Steckler, K. B. Welch, E. K. Inskeep, and V. Padmanabhan Fetal Programming: Prenatal Testosterone Treatment Leads to Follicular Persistence/Luteal Defects; Partial Restoration of Ovarian Function by Cyclic Progesterone Treatment Endocrinology, April 1, 2006; 147(4): 1997 - 2007. [Abstract] [Full Text] [PDF]

				M. E. Lujan, A. A. Krzemien, R. L. Reid, and D. A. Van Vugt Developing a Model of Nutritional Amenorrhea in Rhesus Monkeys Endocrinology, January 1, 2006; 147(1): 483 - 492. [Abstract] [Full Text] [PDF]

				S. Chhabra, C. R. McCartney, R. Y. Yoo, C. A. Eagleson, R. J. Chang, and J. C. Marshall Progesterone Inhibition of the Hypothalamic Gonadotropin-Releasing Hormone Pulse Generator: Evidence for Varied Effects in Hyperandrogenemic Adolescent Girls J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2810 - 2815. [Abstract] [Full Text] [PDF]

				V. Padmanabhan, M. B. Brown, G. E. Dahl, N. P. Evans, F. J. Karsch, D. T. Mauger, J. D. Neill, and J. Van Cleeff Neuroendocrine Control of Follicle-Stimulating Hormone (FSH) Secretion: III. Is There a Gonadotropin-Releasing Hormone-Independent Component of Episodic FSH Secretion in Ovariectomized and Luteal Phase Ewes? Endocrinology, April 1, 2003; 144(4): 1380 - 1392. [Abstract] [Full Text] [PDF]

				C. R. McCartney, M. B. Gingrich, Y. Hu, W. S. Evans, and J. C. Marshall Hypothalamic Regulation of Cyclic Ovulation: Evidence That the Increase in Gonadotropin-Releasing Hormone Pulse Frequency during the Follicular Phase Reflects the Gradual Loss of the Restraining Effects of Progesterone J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2194 - 2200. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, S. M. Pincus, M. C. Garcia-Rudaz, M. G. Ropelato, M. E. Escobar, and M. Barontini Disruption of the Joint Synchrony of Luteinizing Hormone, Testosterone, and Androstenedione Secretion in Adolescents with Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 72 - 79. [Abstract] [Full Text]

				C. L. Pastor, M. L. Griffin-Korf, J. A. Aloi, W. S. Evans, and J. C. Marshall Polycystic Ovary Syndrome: Evidence for Reduced Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Estradiol and Progesterone J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 582 - 590. [Abstract] [Full Text]

				T. L. Daniels and S. L. Berga Resistance of Gonadotropin Releasing Hormone Drive to Sex Steroid-Induced Suppression in Hyperandrogenic Anovulation J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4179 - 4183. [Abstract] [Full Text] [PDF]

				A. Arroyo, G. A. Laughlin, A. J. Morales, and S. S. C. Yen Inappropriate Gonadotropin Secretion in Polycystic Ovary Syndrome: Influence of Adiposity J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3728 - 3733. [Abstract] [Full Text] [PDF]

				A. E. Taylor, B. McCourt, K. A. Martin, E. J. Anderson, J. M. Adams, D. Schoenfeld, and J. E. Hall Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2248 - 2256. [Abstract] [Full Text] [PDF]

				V. Padmanabhan, K. McFadden, D. T. Mauger, F. J. Karsch, and A. R. Midgley Jr. Neuroendocrine Control of Follicle-Stimulating Hormone (FSH) Secretion. I. Direct Evidence for Separate Episodic and Basal Components of FSH Secretion Endocrinology, January 1, 1997; 138(1): 424 - 432. [Abstract] [Full Text] [PDF]